Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEG-loxenatide plus canagliflozin versus metformin plus canagliflozin in high-risk type 2 diabetes
ChiCTR2100045608Phase 4Recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Apr 2021
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of polyethylene glycol loxenatide, canagliflozin and metformin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by West China Hospital of Sichuan University. Primary endpoint: HbA1c. Started Apr 2021; status: recruiting.
02
Drugs
polyethylene glycol loxenatidecanagliflozinmetformin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR2100045608.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100045608.